Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001062993-25-010580
Chunk: 242

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B3
Chunk 242
---
 pronouncements have had or will have a material impact on its financial position or operating results.

<div align='center'>F-33</div>

3. Balance sheet components Prepaid expenses and other current assets include the following:

|                                              |   | March 31, 2025 |     |   | December 31, 2024 |
|:---------------------------------------------|:--|---------------:|:----|:--|------------------:|
|                                              |   |     -Unaudited |     |   |                   |
| Insurance                                    | $ |        408,938 |     | $ |           583,561 |
| Contract research organizations              |   |        355,810 |     |   |           455,810 |
| Professional services                        |   |        250,109 |     |   |           144,643 |
| Prepaid services                             |   |         76,488 |     |   |            29,970 |
| Receivable for proceeds of warrant exercises |   |         14,000 |     |   |                 - |
|                                              | $ |      1,105,345 |     | $ |         1,213,984 |

Accrued expenses and other current liabilities include the following:

|                                   |   | March 31, 2025 |     |   | December 31, 2024 |
|:----------------------------------|:--|---------------:|:----|:--|------------------:|
|                                   |   |     -Unaudited |     |   |                   |
| Accrued legal fees                | $ |        553,835 |     | $ |           495,016 |
| Accrued compensation and benefits |   |         89,701 |     |   |           140,989 |
| Accrued other                     |   |        418,504 |     |   |           126,830 |
|                                   | $ |      1,062,040 |     | $ |           762,835 |

4. Leases As of March 31, 2025, the Company had one operating lease for its corporate office that commenced in 2024, for which the Company recorded a right-of-use asset and lease liability as of the commencement date. The Company's lease does not contain a purchase option. Where the Company's lease contains an option to extend the lease term, the extended lease term is only included in the measurement of the